AI-Powered 'Depression Thermometer' to Aid Interventional Psychiatry Network

NRx Pharmaceuticals partners with Emobot to integrate innovative mental health monitoring technology across clinics

Mar. 30, 2026 at 7:21pm

Got story updates? Submit your updates here. ›

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has announced a strategic partnership with Emobot Health to deploy the company's AI-driven 'Depression Thermometer' across NRXP's growing network of interventional psychiatry clinics. This integration represents the first large-scale clinical implementation of Emobot's passive monitoring technology, designed to detect early treatment response and prevent relapse in patients with Treatment-Resistant Depression (TRD).

Why it matters

The partnership aims to enhance patient care and outcomes by providing clinicians with real-time, data-driven insights into their patients' mental health status. This aligns with the broader shift towards neuroplastic therapies, including IV ketamine, esketamine, and transcranial magnetic stimulation, which have shown promise in treating severe and suicidal depression where traditional oral antidepressants have fallen short.

The details

Emobot's 'Depression Thermometer' replaces cumbersome psychometric questionnaires with a background smartphone application that passively and automatically measures levels of depression, suicidality, and PTSD. This data will be integrated into NRXP's interventional psychiatry clinics, which offer a range of neuroplastic treatments, including ketamine, TMS, and hyperbaric oxygen therapy, combined with physician-led psychotherapy. The partnership aims to improve patient monitoring, early detection of relapse, and overall treatment outcomes.

  • On March 30th, 2026, NRXP announced the strategic partnership with Emobot Health.
  • In 2025, NRXP opened its first interventional psychiatry clinic in Palm Beach, Florida, which is now accepting patients.

The players

NRx Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD.

Emobot Health

A company that has developed an AI-powered 'Depression Thermometer' technology to passively and automatically monitor levels of depression, suicidality, and PTSD using a smartphone application.

Prof. Joshua Brown, MD, PhD

The newly appointed Chief Medical Innovation Officer at NRXP, who is a principal investigator on NIH- and DARPA-funded projects exploring the use of neuroplastic therapies, including TMS and D-cycloserine, for treating depression, PTSD, and suicidality.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with Emobot to integrate their innovative 'Depression Thermometer' technology across our growing network of interventional psychiatry clinics. This will provide our clinicians with real-time, data-driven insights to enhance patient care and improve outcomes for individuals struggling with severe and treatment-resistant depression.”

— Robert Besthoff, CEO, NRx Pharmaceuticals

“Emobot's passive monitoring technology represents a significant advancement in the way we can track and respond to mental health conditions. We're proud to partner with NRXP to bring this cutting-edge solution to their network of specialized clinics, where it can have a meaningful impact on patient lives.”

— Lena Berthelsen, CEO, Emobot Health

What’s next

NRXP and Emobot plan to roll out the 'Depression Thermometer' technology across NRXP's network of interventional psychiatry clinics throughout 2026, with the goal of providing clinicians with real-time data to enhance patient monitoring and improve treatment outcomes for individuals struggling with severe and treatment-resistant depression.

The takeaway

The partnership between NRXP and Emobot represents a significant step forward in the integration of innovative digital health technologies into the delivery of specialized, neuroplastic-based mental health care. By providing clinicians with data-driven insights into their patients' mental health status, this collaboration aims to improve the detection and management of severe and treatment-resistant depression, ultimately leading to better outcomes for those in need of advanced psychiatric interventions.